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ABSTRACT  
 
Aims  
 
To determine the incidence of unintended medication discrepancies in paediatric patients 
at the time of hospital admission; evaluate the process of medicines reconciliation; assess 
the benefit of medicines reconciliation in preventing clinical harm.   
Method:  
A five month prospective multisite study.  Pharmacists at four English hospitals conducted 
admission medicines reconciliation in children using a standardised data collection form. 
A discrepancy was defined as a difference between the patient’s Pre-Admission 
Medication (PAM), compared with the initial Admission Medication Orders written by the 
hospital doctor.  The discrepancies were classified into intentional and unintentional 
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discrepancies. The unintentional discrepancies were assessed for potential clinical harm 
by a team of healthcare professionals, which included doctors, pharmacists and nurses.   
Results:  
 Medicines reconciliation was conducted in 244 children admitted to hospital.  45% 
(109/244) of the children had at least one unintentional medication discrepancy between 
the Pre-Admission Medication and Admission Medication Order.  The overall results 
indicated that 32% (78/244) of patients had at least one clinically significant unintentional 
medication discrepancy with potential to cause moderate 20% (50/244) or severe 11% 
(28/244) harm. No single source of information provided all the relevant details of a 
patient’s medication history. Parents/carers provided the most accurate details of a 
patient’s medication history in 81% of cases. 
Conclusion:    
This study demonstrates that in the absence of medicines reconciliation, children admitted 
to hospitals across England are at risk of harm from unintended medication discrepancies 
at the transition of care from the community to hospital.  No single source of information 
provided a reliable medication history.   
 
Main manuscript  
INTRODUCTION 
 
Medicines reconciliation is an intervention that reduces medication errors that occur at 
transitions in care for hospitalised patients.[1] Adult studies have shown that 60% of 
patients experience at least one unintended medication discrepancy upon admission or 
discharge, of which 18% have at least one clinically important discrepancy.[2] 
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 The UK has incorporated medicines reconciliation as a priority area for national 
patient safety, with national guidance in place for conducting medicines reconciliation in 
adults upon admission to hospital.[3]  The guidance excluded children under the age of 16 
years.[3]   
 Based on findings from a recent review of the literature regarding medication 
discrepancies at transitions in hospital care for children, there is limited evidence 
concerning the epidemiology of medication discrepancies across the interface of health 
care settings.[4] The review revealed only one UK study that evaluated the epidemiology 
of medication discrepancies at hospital admission and was limited to one neurosurgical 
ward at a children’s hospital.[5]    This study revealed that for 100 admissions, 39% of 
medications written at hospital admission had a discrepancy when compared with the 
patient’s pre-admission medication list, of which half had the potential to cause moderate 
or severe harm to the patient if left unresolved.[5]   The review found that there were 
studies of medication discrepancies in North America which focused on medically complex 
children (USA) or was undertaken at a single site general medicine setting (Canada).[6,7]  
One particular study observed the accuracy of various sources of information to obtain an 
accurate medication history as an outcome measure.[8]  Since the review was published, 
there has been one further published abstract observing the medication discrepancies of 
admission medications in Ireland. However this was also single site and had a small 
sample size. [9] 
 
Based on the current limited evidence, this present study was conducted to determine if 
paediatric patients across England were at risk of clinically important discrepancies at 
hospital admission.[5]   The primary objective was to prospectively identify the incidence of 
medication discrepancies that occurred at the time of hospital admission, prior to 
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medicines reconciliation.  The secondary objectives were to: evaluate the process of 
obtaining the medication history in terms of the time required for the process and the 
source and quality of information; and to assess the potential adverse clinical impact that 
unintended discrepancies identified may have, in the absence of medicines reconciliation.   
METHOD 
 
The study was conducted at paediatric hospital wards across all available specialities of 
four hospital sites providing secondary and tertiary care in Birmingham, Leeds, London 
and North Staffordshire in England.   
 
The study cohort included children that were admitted over a 5 month study period, and 
prescribed at least one long-term medication.  Long-term medication was defined as a 
medication that was prescribed for the child and expected to be taken on a repeat basis for 
three months or longer.   Children were excluded from the study if: they were aged 19 
years or older; the parent or carer was not available for interview; the drug chart was not 
accessible at the time of the data collection; or if the data collection could not be 
completed for practical reasons such as admission taking place out of hours in the 
evenings or during weekends (they would still receive routine care). 
Medicines reconciliation was conducted by a clinical pharmacist who received training on 
using a pre-defined data collection form.    Information concerning the child’s diagnosis, 
age and weight, and speciality of the ward admitting the child were recorded.  The 
following information retrieval processes were undertaken to support the medicines 
reconciliation:  
- A semi-structured interview of the child’s parent or carer to obtain a medication 
history and subsequently securing their permission to contact their community 
doctor, referred to as their General Practitioner (GP) in England  
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- The determination of the child’s medication history record, obtained by telephoning 
the child’s GP practice 
- Recording details of the Patient’s Own Drugs (PODs) that were brought into 
hospital on admission 
- Recording the initial Admission Medication Orders (AMOs) from the hospital drug 
chart prior to clinical pharmacist input 
- A pharmacist determined regimen(s) was established based on the information 
gathered, and their clinical judgement as to what the patient should be prescribed in 
terms of long-term medications at the time of admission 
 
The length of time it took to obtain the required information was also recorded. 
Prior to the data collection, there was no specified procedure for medicines reconciliation 
in children. The approach to reconciliation in children, and sources used to verify the 
medication history was under the discretion and clinical decision of each clinical 
pharmacist.   
 
For the purposes of identifying any discrepancies in the data collected, the patient’s 
medication record from the GP was defined as the patient’s Pre-Admission Medication 
(PAM) list, and this was compared against the initial Admission Medication Orders (AMOs) 
written by the hospital doctor prior to pharmacist input.  When discrepancies were 
identified, the data collection pharmacist discussed each discrepancy with the prescriber.  
The discrepancies were further classified into intentional or unintentional discrepancies, as 
some of the charted medicines may have been intended changes according to clinical 
need after clarifying with the doctor.  The classification of intentional and unintentional 
discrepancies was initially determined by the data collection pharmacist, usually in 
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consultation with the prescriber, and later validated by a panel of clinical paediatric 
pharmacists from the four sites.   
The clinical significance of the unintentional discrepancies identified was assessed using 
the methodology used by Terry et al adapted from Cornish et al.[5,10] 
A panel of experts consisting of two paediatric clinical pharmacists, two hospital doctors 
and a medicines management nurse (the “Clinical Assessment Panel”) met and 
categorised the discrepancies.  Each discrepancy was considered on a case by case 
basis. The patient’s age and diagnosis were provided to the panel.  
The Clinical Assessment Panel was asked to rank each discrepancy according to potential 
harm using three ordinal classifications based on a theoretical scenario where the 
discrepancies were left unchanged over a period of 7 days: Class 1: - Unlikely to cause 
patient discomfort or clinical deterioration; Class 2: - Potential to cause moderate 
discomfort or clinical deterioration; Class 3: - Potential to result in severe discomfort or 
clinical deterioration.[10]   
The incidence of the unintentional discrepancies was calculated as: -   
number of patients with at least one unintentional discrepancy
total number of patients
 
The incidences of unintentional discrepancies per patient within each of the three 
classifications 1, 2 or 3 were calculated as: - 
number of patients with class 1 (2 or 3) discrepancies
total number of patients
 
Any individual patient could have more than one classification of discrepancy. Therefore a 
further incidence value was calculated based on the number of patients who had class 1, 2 
or 3 expressed as their most serious discrepancy. This was calculated as: -  
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number of patients with a class 1 (2 or 3) discrepancy as the most serious discrepancy
total number of patients
 
 
In addition to collecting information relevant to the medication history, the time to complete 
each process was recorded to determine the time resource required to conduct medicines 
reconciliation.  Once information was collected from all the sources and the pharmacist 
determined regimen was established, the sensitivity of each source of information against 
the pharmacist determined regimen was calculated. 
 
Ethical consideration 
This study was deemed a service evaluation project by the Research & Development 
Department of all sites involved and therefore NHS ethics committee approval was not 
required.    Although NHS ethics was not required, this project was approved by the 
School of Pharmacy, University of London Ethics Committee in 2011.  All data collected 
were anonymised and stored appropriately according to NHS information governance 
procedures.   
RESULTS 
 
 
244 patients were admitted to the study and 1004 individual drug prescriptions were 
recorded.  The age of the patients ranged from 1 month to 16 years of age (median age of 
5 years, Inter-Quartile Range IQR 1.5 years – 11.25 years).  The most common speciality 
associated with the admissions were, general paediatric medicine (n = 80), respiratory (n = 
35) and surgery (n = 31).  See Table 1 for full details of the number of admissions per 
speciality. 
 
The data collection pharmacists identified 582 medication discrepancies from the 1004 
drug prescriptions (58%) affecting 203 patients (83%).  Of the 582 discrepancies, 209 
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were classified as unintentional, 277 were intentional and 96 were reclassified as either 
trivial, relating to nutritional feeds rather than medicines or other (other being 
discrepancies that the team were unable to classify because the drug regimen was not on 
the GP record, nor written up on the hospital drug chart but identified by the pharmacist or 
patient). 
 
The 209 unintentional discrepancies, affecting 109/244 (45%) patients, were classified 
using the method by Terry and colleagues. It was found that 189 drug discrepancies 
affecting 100 patients were unintentional discrepancies and were classifiable into the 
“harm” classifications. In the view of the ‘Clinical Assessment Team’ the remaining 20 
unintentional discrepancies were likely to be clinically beneficial to the patient and therefore were 
excluded from classification of harm. Nine patients were identified who only had potentially 
beneficial discrepancies were excluded in the clinical assessment for harm. The incidence 
of each class of discrepancy was: 22% (22/100) patients with Class 1 (Unlikely to cause 
patient discomfort or clinical deterioration); 50% (50/100) patients with Class 2 (Potential to 
cause moderate discomfort or clinical deterioration) and 28% (28/100) patients with Class 
3 (Potential to result in severe discomfort or clinical deterioration). 
The overall results indicated that 32% (78/244) of patients in the study had at least one 
clinically significant unintentional discrepancy, rated as moderate Class 2 (50/244) or 
severe Class 3 (28/244) potential harm.  Please see Table 2 for selected examples 
highlighting Class 1, Class 2 and Class 3 discrepancies. 
 
The total time required for completing medicines reconciliation for each of the 244 study 
patients ranged from 6 to 144 minutes (Median 24, Inter-quartile range 17 – 40).   
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A comparison of the pharmacist determined regimen (a decision the pharmacist made at 
the conclusion of the medicines reconciliation process) against the sources of information 
used showed that the parent-carer provided the most accurate information by matching 
81% of the pharmacist determined regimens.  Parents were able to identify all their child’s 
medication in 71% of admissions, with 15% being able to identify some but not all of their 
child’s medication regimens based on a comparison against the pharmacist determined 
regimen.  The pre-admission medication list from the GP matched the pharmacist 
determined regimen in 70% of cases.  Patient’s own drugs (PODs) were only present in 94 
admissions and only 56% (53/94) of PODs that were available at admission were of use 
and matched the pharmacist determined regimen.  In 7.4% of cases, there were conflicting 
information between all the sources of information gathered and the pharmacist made the 
recommendation based on clinical judgement and a review of the patient notes.   
 
DISCUSSION 
 
This study found that medication discrepancies occurred at hospital admission when 
admission medication orders were written by prescribers in the absence of medicines 
reconciliation.  Almost half of patients who were admitted to hospital on at least one long 
term medication experienced one or more unintended medication discrepancies. Of this 
cohort one in five patients were at risk of moderately (class 2) clinical harm and one in ten 
were at risk of serious clinical harm (class 3).  The findings of this present study add to 
current evidence that in the absence of medicines reconciliation, medication discrepancies 
occur across the paediatric population in England. As this study was carried out across 
four geographically different hospital settings with variations in health service delivery, the 
findings may be generalizable to the paediatric population nationally and internationally, 
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but further investigations are required to confirm this.  A later study that was conducted in 
a paediatric hospital setting in Ireland found that 37.5% of patients (15 out of 40 patients) 
from a single hospital site in Ireland had at least one undocumented discrepancy on their 
drug Kardex.  Further details of whether or not these undocumented discrepancies were 
intended or unintended were not provided in the abstract report.[9] Although the sample 
size for the study in Ireland was small, the comparable rates suggest that the results of our 
study may be generalizable.     
  Two additional outcome measures were evaluated during the course of our study.  
The first was the sensitivity of each source of information and it was found that the 
parent/carer was the most sensitive (accurate) source of information, followed by the GP 
and the patient own drugs (PODs). PODs were seen as a less accurate source since they 
are infrequently brought into hospital and thus by default will not give all the data required. 
The finding that the parents were the most reliable source of information supports previous 
studies observing the information sources that made up a medication history in a child [8].  
However a study sited in USA observed that approximately half of parents were not 
available within the first 18 hours of admission in medically complex children [6], although 
this was not apparent in our study.  Many parents expressed the dose of liquid medicines 
in terms of volume alone (e.g. millilitres). This highlights the importance of a second 
source of information, either the GP of POD, to confirm the actual dose required (e.g. 
milligrams). This is particularly important when prescribing for children due to the variety of 
unlicensed preparations available.  An important finding is that the GP who is responsible 
for the care of the patient outside hospital did not hold all the information regarding the 
patient’s current medication. These findings demonstrate the complexity of correctly 
identifying medicines for children; who are often cared for via several health care providers 
and may have several carers and care settings.  
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The second outcome measured was the time taken to complete medicines 
reconciliation using the data collection forms.  It was found that the median time taken to 
conduct medicines reconciliation was twenty-four minutes per patient and the longest time 
was two hours and twenty-four minutes.  This average value was lower than the estimated 
time reported by a study of medicines reconciliation carried out in medically complex 
children in the USA which was 90 minutes.[6]  The shorter median time may be as the 
present study included all patients who were on at least one long-term medication prior to 
hospital admission and did not restrict or impose criteria to prioritise children with complex 
medication regimens.   
   
As with all studies that have observed medication ‘discrepancies’ at hospital admission, 
there was no single exact or perfect list of medications that a patient was taking prior to 
admission (sometimes referred to as a ‘gold standard’).  Unlike other observational studies 
rather than using a “best possible medication history” list [7] or ‘verified outpatient list’ [6], 
this study utilised the GP as the main reference point to identify pre-admission medication.  
This decision was made during methodology development as the GP was expected to be 
the main gatekeeper of information and hold information on all medications the patient was 
prescribed. However, this study demonstrates the limitation of GP held information.   
 
 This study confirmed that clinically significant medication discrepancies may occur 
in hospitalised children. This is not isolated to one particular speciality or hospital. 
Medicines reconciliation is important in detecting and rectifying these discrepancies.  
Existing studies have explored the completeness of sources of information to obtain 
medication histories [8], or monitored the uptake of medicines reconciliation. [11] However, 
to the best of our knowledge, no studies have been published concerning the design of 
evidence based and user evaluated medicines reconciliation interventions for children. 
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CONCLUSION 
 
This study has demonstrated that children who are admitted to hospitals across England 
are at risk of harm from unintended medication discrepancies in the absence of medicines 
reconciliation.  Of the four sources of information adopted by this study, not one source of 
information could provide a complete medication list, which is similar to studies in adult 
patients.  This finding and the fact that the method used in the study was not common 
practice at the study sites highlights that a more thorough approach of conducting 
medicines reconciliation in the paediatric population is required.  Further work is required 
to design and implement a practical and efficient intervention to reduce harm and 
standardise medicines reconciliation.     
What is already known on this topic 
Medication discrepancies have been shown to occur at hospital admission for 
paediatric patients based in Canada, Ireland, the UK and USA.   
 
Current studies are limited to individual specialties, single hospital sites, and small 
patient samples. 
What this study adds 
Medication discrepancies can occur in paediatric patients who are on long term 
medication, and may cause potentially harmful consequences. 
Medicines reconciliation can resolve potentially harmful unintended medication 
discrepancies in children. 
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